Barry Ticho Sells 2,014 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 2,014 shares of the stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $30.65, for a total value of $61,729.10. Following the completion of the sale, the insider directly owned 15,156 shares of the company’s stock, valued at approximately $464,531.40. The trade was a 11.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Barry Ticho also recently made the following trade(s):

• On Tuesday, December 2nd, Barry Ticho sold 2,006 shares of Stoke Therapeutics stock. The shares were sold at an average price of $29.78, for a total value of $59,738.68.
• On Monday, November 3rd, Barry Ticho sold 5,931 shares of Stoke Therapeutics stock. The shares were sold at an average price of $25.72, for a total transaction of $152,545.32.

Stoke Therapeutics Price Performance

Shares of NASDAQ:STOK opened at $31.05 on Friday. Stoke Therapeutics, Inc. has a 1 year low of $5.35 and a 1 year high of $38.69. The business’s 50-day moving average is $28.90 and its 200-day moving average is $19.69. The company has a market capitalization of $1.77 billion, a price-to-earnings ratio of 46.34 and a beta of 1.14.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.11). The business had revenue of $10.63 million during the quarter, compared to analyst estimates of $6.06 million. Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. Analysts anticipate that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in STOK. Allspring Global Investments Holdings LLC bought a new stake in shares of Stoke Therapeutics in the 2nd quarter worth approximately $402,000. Siren L.L.C. increased its position in Stoke Therapeutics by 12.4% in the first quarter. Siren L.L.C. now owns 2,247,347 shares of the company’s stock worth $14,945,000 after buying an additional 247,347 shares during the last quarter. Aviva PLC bought a new stake in shares of Stoke Therapeutics in the second quarter valued at $499,000. KLP Kapitalforvaltning AS lifted its position in shares of Stoke Therapeutics by 131.6% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 13,200 shares of the company’s stock valued at $150,000 after buying an additional 7,500 shares during the last quarter. Finally, Invesco Ltd. grew its stake in shares of Stoke Therapeutics by 117.0% during the 1st quarter. Invesco Ltd. now owns 26,183 shares of the company’s stock worth $174,000 after acquiring an additional 14,118 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on STOK shares. JPMorgan Chase & Co. raised their price target on shares of Stoke Therapeutics from $15.00 to $25.00 and gave the stock a “neutral” rating in a report on Monday, November 3rd. Wedbush upped their target price on Stoke Therapeutics from $22.00 to $32.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 5th. BTIG Research restated a “buy” rating and set a $39.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, November 5th. Canaccord Genuity Group raised their price objective on shares of Stoke Therapeutics from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Stoke Therapeutics in a research report on Monday. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $31.00.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.